LLYEli Lilly and CompanyRunning, no new patients
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Medullary Thyroid Cancer · Infantile Myofibromatosis · Infantile Fibrosarcoma · Papillary Thyroid Cancer · Soft Tissue Sarcoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 36 (final count)
- Started
- Jun 13, 2019
- Main results expected
- Nov 8, 2024
- Fully finished
- May 2029
- Results posted
- Jan 6, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over: Cycle 1 (28 Day Cycle)
Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study
Measured over: Date of first dose to disease progression or death (Up to 62.4 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03899792 · record last updated 2026-01-06 · checked 2026-11-09 15:36 UTC